The Neuroscience Center

  • Home
    • The Neuroscience Center Story
    • Evaluation and Treatment
    • Expertise and Special Interest
  • About Us
    • Steve Best, M.D.
    • Dan G. Pavel, MD
    • John Hughes M.D. Ph.D
    • Petrolino Costa, MD
    • Dr. Michael Easton, MD (Consultant)
    • Brenden Cochran, ND
    • Cindy McKinzie, PsyD, RYT
    • Melanie E. Dillon, MA, LCPC
    • Kyle Ferroly, M.S. BCN
    • John C. LeMay, QEEG-D, MFT, BCB
    • Press
  • What We Do
  • Services
    • Brain SPECT Imaging
    • Hyperbaric Oxygen Therapy
    • TMS/ketamine
    • Ketamine Assisted Psychotherapy (KAP)
    • Dementia Care and Cognitive Impairment Clinic
    • SPRAVATO™ Clinic
    • Correcting Inborn Errors of Metabolism
    • Nutrition Based Intervention
    • Cannabis and CBD Related Services
  • Education
    • Pain
    • Mood
    • Head Injury
    • Stroke
    • Cognitive Impairment
    • Development
    • Substance Abuse
    • Additional Topics
  • Contact
    • Getting Started
    • Patient Information
      • Policy
      • Patient FAQ – Frequently Asked Questions
      • CPT Billing Codes
    • Directions
  • Partners
    • Hyperbaric Centers of Chicago
    • PathFinder Brain SPECT Imaging
    • Entourage Clinical Services
  • Library
    • Patient Resources
    • Provider Resources
    • Blog
You are here: Home / SPRAVATO™ Clinic

SPRAVATO™ Clinic

The Neuroscience Center is an approved site to administer SPRAVATO™ which was recently approved by the Food & Drug Administration as a treatment strategy for Treatment Resistant Depression (TRD). SPRAVATO™ is a type of ketamine, a medication that has been used for years to successfully alleviate the symptoms of TRD. The FDA’s approval of SPRAVATO™ acknowledges the important role that ketamine may have in treating TRD, a condition that impacts millions of people who do not respond to traditional monoaminergic antidepressants.

Because ketamine is classified by the FDA as a Schedule III drug, meaning there is some potential for dependency and abuse, SPRAVATO™ is only available through sites that enroll in a special program called a Risk Evaluation and Mitigation Strategy (REMS) program. TNC is enrolled as a REMS site and adheres to all the safety requirements.

The requirements for eligibility for SPRAVATO™ treatment include:

  • A diagnosis of TRD.
  • Past trials of two different anti-depressants that have not
    resolved the symptoms.
  • Currently taking an anti-depressant medication.
  • Physical exam to rule out contra-indications for SPRAVATO.™
  • Insurance preauthorization.

A typical course of SPRAVATO™ may include two treatments per week for one month, followed by one treatment per week for one month, followed by an ongoing pattern of treatments. In accordance with the SPRAVATO™ guidelines, please anticipate being in our clinic for at least two hours as the protocol requests monitoring of blood pressure and possible side effects such as sedation, dizziness, dissociation, or nausea. Due to these possible side effects, patients are required to have a safe ride home with a trusted friend or family member.

The Neuroscience Center has a long history of expertise in assessment, diagnosis, and treatment using ketamine-based therapies for Treatment Resistent Depression. Given our experience with ketamine and TRD, we have the knowledge, environment, medical, and psychological support to ensure a safe experience with this medication.

If you are interested in SPRAVATO™and would like to see if you qualify for the medication, please fill out our patient contact form  and we will contact you for a free phone consultation.

Copyright © 2019 · The Neuroscience Center · All Rights Reserved · Terms of Use

440 Lake Cook Road, Building 2, Deerfield, IL 60015 · Office (847) 236-9310

Facebook